title: Potential benefits of alkali therapy to prevent GFR loss: time for a palatable 'solution' for the management of CKD.
abstract: There is increasing evidence that alkali therapy can retard progression of chronic kidney disease (CKD). We summarize recent studies and discuss a mechanism whereby alkali therapy may neutralize acid production associated with typical Western diets, which generate acid. We emphasize the rationale for using alkali therapy early in the course of CKD, even in the absence of overt metabolic acidosis, and we urge the pharmaceutical industry to develop palatable alkali-containing solutions.
authors.affiliation: Division of Nephrology and Hypertension, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
authors.forename: Vaibhav
authors.initials: V
authors.lastname: Sahni
authors.forename: Robert M
authors.initials: RM
authors.lastname: Rosa
authors.forename: Daniel
authors.initials: D
authors.lastname: Batlle
mesh_terms: D000136:Acid-Base Equilibrium; D000138:Acidosis / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D000284:Administration, Oral; D000450:Aldosterone / Q000097:blood; D000818:Animals; D001639:Bicarbonates / Q000008:administration & dosage*; D002908:Chronic Disease; D019587:Dietary Supplements; D018450:Disease Progression; D019332:Endothelin-1 / Q000097:blood / Q000187:drug effects; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D001639:Bicarbonates; D019332:Endothelin-1; D000450:Aldosterone; C031556:calcium bicarbonate